I was born on 6 August 1956 in San Francisco, California to Janet and (the late) Richard Hovis.
I grew up in Santa Monica, California where I attended elementary, junior high school, and high school (graduating in 1974), in addition to involvement in sports and recreation (Little League +, the Boy’s Club ++). Further, it was in elementary school – St. Augustine’s By-the -Sea Parish School that I found, and made the choice to truly journey with God.
I attended Arizona State University from 1974 to 1977 – seeking to become an architect, however, I was not accepted, and, as such, I graduated with a Liberal Arts degree.
Upon graduation from Arizona State University, I attended Cal Poly San Luis Obispo and studied City and Regional Planning at the Master’s level. I successfully completed one (1) year in a two (2) year program – I did not complete the Master’s degree in City and Regional Planning – due to personal reasons.
I returned to Santa Monica where I started (October 1979) my career as graphic designer with Exxon Company, USA. I spent five years with Exxon Company, USA.
While working with Exxon Company, USA I was accepted into architectural school – Sci-Arc in Southern California, however, I did not attend preferring to stay with Exxon..
In 1982 I married Laura Flosi and in April 1983 we had our one and only child – Lauren Alain Hovis – a gift from God.
We moved to Phoenix, Arizona in 1984 from Los Angeles, where I went to work as a graphic designer with Kitchell CEM (from 1985 -1987).
From 1987 – 1995 I was an independent contractor, and a registered representative in mortgage finance, financial management, graphic design, and drafting.
Further, I attended the University of Phoenix and successfully obtained a Master’s in Business Administration (MBA) in 1982.
I was also a member of the Scottsdale Jaycees, where I became very involved in community events and projects.
In 1994, I accepted a cartography position with the Defense Mapping Agency in Reston, Virginia. As such, I relocated from Phoenix to Reston.
In 1998, I was accepted and worked as a Visual Information Officer with the Central Intelligence Agency. In 2002, I worked as a Support Officer until my retirement (due to a need for shoulder surgery) in September 2018.
Away from my Federal Government service, I have been involved in various organizations and activities in Northern Virginia.
In November of 2011, I married Rebecca Ouellette in Santa Monica, California. I reside in San Tan Valley, AZ with my two hamster - Jess and Timothy, our fish, our lizard - RJ Lizard., and our cats - Pearl and Grey.
As to hobbies, I enjoy playing sports, attending sporting events, mentoring individuals from financial management to hamsters, building models, photography, travel, multimedia design, managing partner for RJ Hamster, and jazz – smooth jazz to a samba or a bossa nova.
Love and God Bless,
Peter – aka RJ Hamster Jo hi
The real struggle with credit card debt isn’t just the balance — It’s the sky-high interest that keeps piling up, making it feel like you’re stuck in place no matter how much you pay.
But this St. Patrick’s Day, there’s a little luck on your side.☘️
CardCritics has rounded up the best balance transfer cards that let you pause interest for nearly 2 years, so your payments can actually go toward paying down your balance — not just the interest.
These cards can make a real difference with: 🧾 0% intro APR on balance transfers 💰 Major savings on interest — potentially hundreds or even thousands 🚫💳 $0 annual fees — so you’re not paying just to keep the card
This email is never sent unsolicited. You have received this Newsmax email because you subscribed to it or someone forwarded it to you. To opt out, see the links below.
Remove your email address from our list or modifyyour profile. We respect your right to privacy. Viewour policy.
This email was sent by: Newsmax.com 362 N. Haverhill Road West Palm Beach, FL 33415 USA
The Permanent Campaign is brought to you today in partnership with Inside Scoop
Issue: 3/16/2026
$10B TikTok Fee for White House
The Trump administration is set to collect roughly $10 billion from investors who took control of TikTok’s U.S. operations, according to reports from the Wall Street Journal, a near-unprecedented fee for a government’s role in brokering a private deal.
Oracle, Silver Lake, and Abu Dhabi investor MGX paid the Treasury about $2.5 billion at the deal’s close in January, with additional payments scheduled to continue until the total reaches $10 billion.
Vice President JD Vance has said the new U.S. entity is valued at about $14 billion, a figure some analysts say dramatically undervalues the platform and its 170 million American users. The deal adds to a growing list of administration moves extracting value from the private sector, including a 10% stake in Intel and a cut of Nvidia chip sales to China.★★★ Iran Rejects Talks with US
President Trump said Saturday that Iran wanted to make a deal but that the terms weren’t good enough, demanding Tehran abandon its nuclear ambitions and adding that he’s hearing the new supreme leader may “not be alive”.
Iran’s foreign minister fired back Sunday, saying Tehran has never asked for a ceasefire and insisting the new leader is in “good health,” though he has yet to appear publicly.
Israel said it struck more than 200 targets across Iran on Sunday alone, expanding operations into western and central Iran, while Gulf states reported fresh waves of Iranian drone and missile attacks.
Germany became the first major ally to publicly decline Trump’s call for warships in the Strait of Hormuz, though South Korea, Britain, and Japan said they were reviewing the request.★★★ Trump Rallies World on Hormuz
President Trump is building an international coalition to reopen the Strait of Hormuz, telling reporters aboard Air Force One he’s spoken to “about seven” countries about sending warships to secure the critical waterway.
Defense Secretary Pete Hegseth is deploying the USS Tripoli and its Marine expeditionary unit to the region as Brent crude hovers near $105 a barrel.
Trump posted on Truth Social that the U.S. has “destroyed 100% of Iran’s Military capability” but acknowledged lingering threats from drones and mines, vowing to keep “bombing the hell out of the shoreline” until the Strait is open.
He also spoke on Sunday by phone with U.K. Prime Minister Keir Starmer about reopening Hormuz to end the disruption to global shipping. Texas Runoff Heats Up
MAGA voters are pressuring Trump not to endorse Sen. Cornyn in his May 26 runoff against AG Ken Paxton, who offered to drop out if the Senate kills the filibuster to pass the SAVE Act. Trump has yet to pick a side.
★★★ Senate Map: GOP Plays Offense
Fox News Digital’s new breakdown of the top 10 Senate battlegrounds shows Republicans eyeing flips in Georgia and Michigan while defending open seats in Maine, North Carolina, Iowa, and Alaska.
★★★ Wiles Diagnosed, Staying on the Job
President Trump announced Monday that Chief of Staff Susie Wiles has been diagnosed with early-stage breast cancer and will begin treatment immediately while continuing to work full-time at the White House. Trump called her prognosis “excellent.”
ICE Scales Up Detention
ICE plans to boost detention capacity to 92,600 beds under a $38 billion overhaul, including eight mega-centers and 16 processing sites, funded through the One Big Beautiful Bill.
★★★ Mullin Hearing Wednesday
Sen. Markwayne Mullin’s confirmation hearing to lead DHS is set for March 18 before the Senate Homeland Security Committee, chaired by Sen. Rand Paul. Trump wants him in the job by month’s end.
★★★ SAVE Act Floor Takeover
Trump allies led by Sen. Mike Lee are planning a Senate floor takeover this week to force a marathon debate on the SAVE America Act, modeling it after the 60-day battle that preceded the 1964 Civil Rights Act.
Today’s section is brought to you by:
These Sheets Prevent 99.7% of Bacteria (And Feel Better Than a Hotel Bed). Say goodbye to stale, sweaty sheets.Miracle Made’s silver-infused bedding stays cooler and fresher, helping prevent up to 99.7% of bacteria growth—so you can enjoy a cleaner, more comfortable, hotel-fresh sleep every single night. (LEARN MORE)
Trump Approval Jumps to 44% — Trump at 44% approve, 54% disapprove, with a Presidential Approval Index of -15. Thirty percent strongly approve while 45% strongly disapprove.
Senate Battleground — Fox News Digital’s analysis of the top 10 Senate races shows Republicans defending seats in Maine, North Carolina, and Alaska while eyeing flips in Michigan and Georgia.
SAVE Act Popular — A Harvard CAPS/Harris poll found 71% of registered voters support the SAVE America Act’s voter ID and proof-of-citizenship requirements — yet every Senate Democrat has vowed to filibuster it.
Iran War Successful — Sixty-one percent of likely voters say Operation Epic Fury has been successful so far, including 35% who call it “very successful.” Just 29% disagree.
Art of the Deal, TikTok Edition The White House is pocketing $10 billion just for brokering a deal that saved 170 million users’ favorite app and kept American data on American soil. Try getting that kind of return from a government program.
Iran’s Phantom Leader Trump openly questioned whether Mojtaba Khamenei is even alive. The new supreme leader hasn’t appeared publicly, hasn’t spoken on camera, and his “first statement” was read by a news anchor holding a framed photo. Not exactly a show of strength from Tehran.
Obama’s Own Guys Say Dems Are Cooked Two former Obama campaign managers told Axios the Democratic Party is a directionless mess. Jim Messina admitted the party’s midterm strategy is “85-90% driven by opposition to Trump” with no affirmative message. David Plouffe warned Dems can’t win “in what are now red states.” When Obama’s brain trust says you’re lost, you’re lost.
Cuba Is Next While Iran burns, Cubans are torching Communist Party headquarters as Trump’s diplomatic moves spark hope across the island. House Intel Chair Rep. Rick Crawford says flat-out: “Cuba is done. It’s just now a question of when, not if.” The dominoes are falling.
Michigan Synagogue Attack: The Threat Is Here The attacker who stormed a Michigan synagogue and kindergarten last week was a Lebanese national who lost family members in Israeli strikes on Lebanon. The FBI is investigating it as a targeted act of violence against the Jewish community. This is exactly the kind of threat Trump warned about when he secured the border.
“Iran wants to make a deal, and I don’t want to make it because the terms aren’t good enough yet.” -President Donald Trump, NBC News interview, March 14, 2026
Trump’s GENIUS Act has given crypto its first official federal framework. While attention stays on Bitcoin, one overlooked coin could benefit the most—backed by skyrocketing volume, early fund activity, and pro-crypto policy momentum.
The market’s holding its breath. US equity futures slipped lower Tuesday morning while oil prices pushed higher, a combination that tells you everything about where investor attention sits right now. The Federal Reserve’s upcoming policy meeting dominates the conversation, and traders aren’t waiting around to find out what happens next. This pre-meeting jitters pattern has become familiar territory.
Miss this and you could miss tomorrow’s best moves. The American Market Brief delivers early insights on sectors, stocks, and market strategies. It’s free, fast, and clear.
Privacy Policy / DisclosuresAdvertising Disclosure: This email contains paid advertisements. This email is from our associates at The Wealthiest Investor.
Legal Entity Information: The Wealthiest Investor is owned and operated by Darwin Investor Network, a DBA of The Darwin Agency, Inc.
Disclaimer: Nothing in this email should be considered personalized financial advice. Always conduct your own due diligence when investing. We urge you to read our full disclaimer by clicking on the terms of use link below.
Unsubscribe: You are receiving this email as part of your complimentary subscription to the The Wealthiest Investor E-Letter. If you would like to unsubscribe, you can do so by clicking on the unsubscribe link below.Darwin Investor Network 2319 N Andrews Avenue, Fort Lauderdale, FL 33311 support@thewealthiestinvestor.com | 1-800-496-9838The Wealthiest Investor | Privacy Policy | Terms of Use Unsubscribe | View Online
Editor’s note: As Silicon Valley power players battle to achieve Artificial General Intelligence (“AGI”), a more powerful force threatens to stop AI’s progress dead in its tracks.
According to futurist Eric Fry from our corporate affiliate InvestorPlace, as this critical bottleneck comes to light, investors will witness a market-wide regime change, violently ejecting today’s winners and replacing them with a brand-new class of unexpected companies.
Eric is sharing the full list of companies he says to buy and sell as this $10 trillion market shock unfolds, which you can learn about below…
Dear Reader,
On the morning of August 12, 2024, I sat down in a recording studio in Baltimore and said something that sounded absurd to almost everyone in the room.
I declared that artificial general intelligence (“AGI”) — superhuman AI with its own version of free will — would emerge from Silicon Valley labs in 2026.
At the time, the expert consensus said we had until 2030.
Fast forward to today, and multiple reputable sources are confirming what I predicted: AGI is here.
This is, without question, the most significant technological development in human history.
The market shock is the counterintuitive call nobody wants to hear — but that could save you from ruin…
AGI is the holy grail that Elon Musk, Mark Zuckerberg, and Sam Altman have spent hundreds of billions of dollars racing to achieve.
And now that it’s beginning to emerge… the Magnificent Seven stocks that funded that race are the last place you want your money.
I know how that sounds. But it wouldn’t be the first time one of my absurd calls became tomorrow’s reality.
In 2000, when the Internet boom was still booming — and companies like Cisco were growing revenues by 50% a year — I told my readers to get out of tech.
The crowd called it absurd. The charts called it absurd. The headlines called it absurd.
Then the crash came.
Tech stocks I said to sell fell 64% to 85%. Investors who didn’t listen watched years of gains evaporate almost overnight.
But the readers who followed my buyrecommendations into overlooked, asset-heavy companies?
They saw gains of 159%… 206%… 271%… even 1,004% — while everyone else was picking up the pieces.
Here’s exactly how my buy and sell calls looked, side by side:
That’s what happens when you get out in front of a regime change instead of being run over by it.
I believe we are at that same inflection point right now, except…
This time around, the stakes are even higher…
Beginning April 24, a series of announcements out of the world’s most powerful AI companies will expose cracks in the AGI story that Wall Street is not prepared for.
First, the headlines will insist everything is fine.
Then the selling will start.
By the time the average investor figures out why the biggest names in the market are falling by as much as 50%, it will be too late to protect themselves — let alone position for what comes next.
That’s why I’m hosting FutureProof 2026 onWednesday, March 18, at 1 p.m. Eastern time— a free live event where I’ll release my complete Market Shock Profit Playbook, including 15 stock names and tickers I predict could receive an influx of $10 trillion in capital in the wake of the Market Shock.
The readers who acted on my dot-com calls didn’t wait until after the crash to do so.
I’ll show you exactly which stocks to sell, which to buy, and where I believe the smart money is moving next.
The time to get futureproofed is now.
Sincerely,
Eric Fry Futurist and Senior Analyst, InvestorPlace
You are receiving this e-mail because you are a subscriber to Chaikin Analytics content. To unsubscribe from special offers like this one, click here to unsubscribe.
Published by Chaikin Analytics, LLC.
You’re receiving this e-mail at pahovis@aol.com. For questions about your account or to speak with customer service, call +1 (877) 697-6783 (U.S.), 9 a.m. – 5 p.m. Eastern time or e-mail info@chaikinanalytics.com. Please note: The law prohibits us from giving personalized financial advice.
D-Wave Keeps Delivering Good News—So Why Is It Falling?
Author: Nathan Reiff. Originally Published: 3/11/2026.
Key Points
D-Wave Quantum shares remain down about a third year-to-date despite numerous technological and business successes.
The company’s bookings and revenue have climbed rapidly alongside gross margin, but operating expenses are also climbing, keeping profitability distant for now.
With a major new Fortune 100 client and other sales momentum, D-Wave may test investor patience while it works to bring its financials in line with its valuation.
A longtime speculative play in the risky and emergent quantum computing industry, D-Wave Quantum Inc. (NYSE: QBTS) looks poised to separate true quantum believers from investors who rode its roughly 168% surge in 2025. Despite that rally, D-Wave shares have mostly traded down or flat through 2026; QBTS is down nearly a third year-to-date.
In this short 3-min. video, legendary investor James Altucher reveals the name and ticker symbol of a company he believes will skyrocket as soon as March 26th…
Still, several positive developments that might have reversed the downtrend have emerged in recent months.
Specifically, strong bookings growth, a high-profile new deal, and a shift to a two-pronged technological approach have so far failed to right the QBTS ship.
D-Wave’s Rally, Cut Short in October, Waits for a Reason to Relaunch
To understand D-Wave’s current position, it helps to go back to October 2025, when the selloff began. After reaching about $45 per share in mid‑October, QBTS plunged to less than half that level in the following weeks, before a modest recovery into year‑end. There wasn’t a clear fundamental catalyst for the reversal; it may have been profit‑taking or a growing concern that the hype had outpaced D‑Wave’s tangible progress at the time.
If that concern was driving the selloff, the rally could resume once the company delivers evidence that investors have reasons to be excited beyond general market enthusiasm. That evidence has been building in some respects: well over $30 million in bookings so far in 2026, a 265% increase in gross profit for full‑year 2025, and a gross margin approaching 83% last year.
Financials and Tech-Side Potential May Still Be Mismatched
D-Wave’s financial improvements are notable, but two metrics may keep many investors unconvinced that a $45-per-share valuation is justified. First, revenue remains small—about $25 million in 2025—for a company with a roughly $7 billion market capitalization, even though revenue nearly tripled year‑over‑year. Second, operating expenses rose 46% in 2025 to roughly $121 million.
Revenue is growing faster than expenses, and strong bookings and margins are constructive, but the company still appears some distance from reporting a break‑even or profitable quarter. Valuation is another hurdle: D‑Wave’s price/sales ratio is extremely high (about 286.5) while book value is roughly $2.30 per share. Even with a newly announced agreement with a Fortune 100 company, investors may reasonably question D‑Wave’s near‑term commercial viability based on those metrics.
On the technology side, D‑Wave’s potential is compelling—particularly after completing its acquisition of Quantum Circuits earlier in the year, which added a complementary technology stack and should help streamline system design and build.
Wall Street Analysts Remain Bullish, But Retail Investors May Not Have the Patience
Wall Street remains largely bullish: 14 of 16 ratings are a Buy or equivalent, and the consensus price target sits roughly 92% above current levels.
Retail investors, however, may be less willing to maintain a speculative position in a company that could still be some time away from aligning its financials with its technological promise.
Investors who can tolerate the volatility and believe management will grow revenue, rein in expenses, and differentiate D‑Wave’s quantum offerings from competitors may be early in backing a potential industry leader. That outcome is possible, but it’s far from guaranteed, and the timeline remains uncertain.
This email communication is a sponsored message sent on behalf of i2i Marketing Group, LLC, a third-party advertiser of MarketBeat. Why did I get this message?.
We are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.
If you have questions or concerns about your account, feel free to contact MarketBeat’s South Dakota based support team at contact@marketbeat.com.
The Wall Street Journal is asking whether a stock market crash is coming. Research from Weiss Ratings suggests the first half of 2026 could be very tough for certain stocks as a radical shift hits the market. Some of America’s most popular names could take serious damage. Analysts have identified five stocks you should consider avoiding before this event plays out. If these are in your portfolio, you’ll want to review your positions carefully.
CompanyShare PriceAmount / PeriodYieldPrevious AmountPayout RatioPayable DateAAONAAON$78.68$0.10 quarterly0.45%$0.1030.8%3/30/26 ARHSArhaus$7.43$0.35 special- – – 3/31/26 BPOPPopular$131.70$0.75 quarterly2.11%$0.7524.4%4/1/26 CSGSCSG Systems International$79.99$0.34 quarterly1.71%$0.3264.3%4/1/26 CURBCurbline Properties$26.94$0.17 quarterly2.46%$0.16168.4%4/8/26 DOLEDole$14.71$0.09 quarterly2.18%$0.0964.2%4/8/26 HBANHuntington Bancshares$15.33$0.16 quarterly3.51%$0.1644.6%4/1/26 IGICInternational General Insurance$24.61$1.15 annual4.60%- 7.0%4/6/26 KRPKimbell Royalty$14.70$0.37 quarterly10.21%$0.35225.8%3/25/26 KSSKohl’s$12.89$0.13 quarterly2.91%$0.1321.2%4/1/26 TUYATuya$2.41$0.06- – – 4/21/26 Please note you must purchase shares of these companies by the market close today to receive the next dividend payment.7 High-Yield Dividend Stocks You Need to See (ad)
7 High Yield Dividend Stocks to Buy Now 💰
Love steady payouts? This free report reveals 7 high-yield dividend stocks you need to know about. From Company #3, a tobacco giant innovating with smokeless products, to Company #4, famously known as “The Monthly Dividend Company,” these picks deliver steady income you can count on.
CompanyShare PriceAmount / PeriodYieldPrevious AmountPayout RatioPayable DateAINAlbany International$54.18$0.28 quarterly1.88%$0.28-55.4%4/7/26 ALNTAllient$62.96$0.03 quarterly0.20%$0.039.1%4/3/26 ASOAcademy Sports and Outdoors$50.50$0.15 quarterly1.00%$0.139.5%4/10/26 BMAMacro Bank$66.37$0.40 monthly6.44%$0.38145.9%3/27/26 CNQCanadian Natural Resources$48.71$0.63 quarterly5.57%$0.5945.5%4/7/26 HLNEHamilton Lane$101.62$0.54 quarterly1.59%$0.5438.8%4/6/26 IFFInternational Flavors & Fragrances$71.45$0.40 quarterly2.05%$0.40-116.8%4/10/26 INSWInternational Seaways$67.91$0.12 quarterly0.66%$0.127.7%3/30/26 MSIMotorola Solutions$468.03$1.21 quarterly1.03%$1.2137.9%4/15/26 NWGNatWest Group$15.60$0.627.43%- 27.9%5/5/26 PSOPearson$13.34$0.233.64%- – 5/15/26 RBCAARepublic Bancorp$69.06$0.50 quarterly2.64%$0.4526.8%4/17/26 SBSWSibanye Gold$13.31$0.26 annual1.64%- – 4/2/26 TNLTravel + Leisure$70.37$0.60 quarterly3.44%$0.5665.7%3/31/26 TPBTurning Point Brands$92.59$0.08 quarterly0.22%$0.089.6%4/10/26 VSTVistra$163.14$0.23 quarterly0.53%$0.2341.9%3/31/26 WHWyndham Hotels & Resorts$77.73$0.43 quarterly2.33%$0.4166.4%3/30/26 WMTWalmart$126.04$0.25 quarterly0.79%$0.2434.3%4/6/26 ZIMZIM Integrated Shipping Services$26.88$0.88 quarterly12.09%$0.311.5%3/26/26 Please note you must purchase shares of these companies by the market close tomorrow to receive the next dividend payment.
Dividend Stock Ideas
This is a list of companies that meet common criteria that investors use to evaluate dividend stocks. This list contains companies that have dividend yields greater than 3%, payout ratios of less than 75% (or less than 100% for REITs), five-year average annual dividend growth of at least 1.5% and a minimum market cap of $1 billion.CompanyDividend YieldAnnual PayoutPayout RatioAnnual Dividend GrowthP/E RatioMarket CapTBCGTBC Bank Group PLC9.32%GBX 886.6034.95%5.29%1.68£2.35KPRGOPerrigo Company plc11.93%$1.16N/A5.21%N/A$1.39KUKWGreencoat UK Wind PLC10.87%GBX 10.09N/A1.86%N/A£2.09KPKPark Hotels & Resorts Inc.9.52%$1.00N/A17.32%N/A$2.12KCAGConagra Brands8.73%$1.40N/A10.50%N/A$7.80KBMEB&M European Value Retail S.A.7.37%GBX 1560.73%2.73%7.27£1.80K
Thank you for subscribing to DividendStocks.com’s daily newsletter!
DividendStocks.com provides a daily email newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news. DividendStocks.com is a subsidiary of MarketBeat Media, LLC and MarketBeat.com.
If you have questions or concerns about your account, don’t hesitate to contact MarketBeat’s U.S. based support team at contact@marketbeat.com.
SMX Emerges as a Critical Shield for U.S. National Security as Iran Conflict Threatens Rare Earth Flows
The strategic importance of rare earth minerals has skyrocketed amid the rising confrontation between the United States and Iran, as these materials underpin the technology, defense, and energy sectors that power national security.
Australia, a leading producer of rare earths, faces pressure to provide secure, verifiable, and compliant supply chains to meet U.S. demands. SMX (Security Matters) Public Limited (NASDAQ: SMX) offers a transformative solution: a molecular identity platform that embeds an indelible, verifiable signature into each mineral, enabling precise origin tracking from mine to market.
By converting supply chains into intelligent, self-verifying networks, SMXaddresses vulnerabilities that can otherwise be exploited during geopolitical instability, including counterfeiting, tampering, and unauthorized diversion of critical resources.
Operating from Singapore and leveraging Southeast Asia’s stable environment, SMX delivers a globally neutral, resilient, and scalable platform for supply-chain security.
Its technology not only verifies materials but strengthens regulatory compliance, industrial accountability, and defense readiness.
In times of conflict, such as the current Iran-U.S. tensions, this capability becomes indispensable: it ensures that essential rare earths are authenticated, traceable, and shielded from interference.
For governments, multinational enterprises, and defense partners, SMXrepresents more than innovation—it is a safeguard against uncertainty, a reinforcement of national security, and a commitment to transparency in a world where trust is fragile.
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to grow to $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancers with tailored mechanisms. Fortunately, a number of promising treatments have shown strong potential—and with that comes the possibility of significant sales.
Two smaller biotech companies are enjoying notable share-price momentum thanks to their leading oncology medicines. Beyond therapeutic promise, these drugs could help the firms move toward greater stability and, potentially, long-term profitability. That said, both remain high-risk investments: each faces clinical, regulatory, or commercial hurdles that could limit upside even as the rewards for success are substantial.
Iovance’s Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked market trends in early March, jumping nearly 37% in a week when the S&P 500 slipped about 1%. That rally added to IOVA’s strong year-to-date performance, with shares more than doubling so far. Still, with a consensus price target of $8.88, Wall Street sees further upside—implying roughly 71% more gains from current levels.
The main catalyst behind Iovance’s move is its lead therapy, Amtagvi, a T‑cell immunotherapy for certain types of melanoma.
Amtagvi has been approved in the United States since 2024 and is building commercial momentum, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company’s IL‑2 immunotherapy, management believes Amtagvi could exceed $1 billion in peak annual U.S. sales.
Its potential may extend beyond melanoma: Amtagvi received FDA Fast Track designation for non‑small cell lung cancer and is being evaluated for other tumor types.
Some of Iovance’s outperformance this year also reflects its Q4 2025 earnings report, issued in late February, in which the company posted narrower‑than‑expected losses per share and reported $5 million in revenue. For the full year, revenue rose roughly 30% year over year.
Iovance is still considered a small (about $2 billion) biotech, and despite the rally, analysts remain cautious—about half of its roughly dozen ratings are Hold or Sell. Risks are significant: in addition to typical small‑biotech concerns, Amtagvi is a personalized therapy that is costly and complex to manufacture. That manufacturing profile could constrain margins and profitability even as demand increases.
Massive Sales Growth for ImmunityBio’s Bladder Cancer Drug
Although ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, its year‑to‑date performance far outpaces Iovance’s. IBRX shares are up nearly 300% in 2026, and analysts remain optimistic: the consensus price target is $13.60, roughly 70% above the stock’s current level.
ImmunityBio’s primary growth driver is Anktiva, a treatment for certain forms of bladder cancer. In February, shares jumped after the E.U. regulator granted conditional marketing authorization—one of several recent approvals globally.
Anktiva is already material to the company’s top line: the drug generated $113 million in sales last year, a roughly 700% year‑over‑year increase.
Like Amtagvi, Anktiva may have potential in other cancer indications, and ImmunityBio is actively exploring additional regulatory designations.
Despite the strong recent performance, IBRX remains speculative and risky.
The company reported a full‑year net loss of $351 million for 2025 as R&D and other expenses remain elevated. Analysts, however, are relatively bullish on ImmunityBio compared with Iovance: six out of seven covering the stock rate it a Buy or equivalent.
Thank you for subscribing to The Early Bird, MarketBeat’s 7:00 AMnewsletter that covers stories that will impact the stock market each day.
This email communication is a sponsored message provided by SmallCaps Daily, a third-party advertiser of The Early Bird and MarketBeat.
This message is a paid advertisement for SMX (NASDAQ: SMX) from SmallCaps Daily and Interactive Offers. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $13,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either SmallCaps Daily or Interactive Offers. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding SMX (NASDAQ: SMX) on Interactive Offers’ website for additional information about the relationship between Interactive Offers and SMX (NASDAQ: SMX).
If you need help with your subscription, feel free to contact our South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC. All rights reserved. 345 N Reid Pl., Suite 620, Sioux Falls, S.D. 57103-7078. United States..
RJ Hamster 